Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute myeloid leukemia with t(6;9)(p23;q34) is a rare subtype of acute myeloid leukemia with recurrent genetic abnormalities characterized by clonal proliferation of poorly differentiated myeloid blasts in the bone marrow, blood, or other tissues in patients who present the t(6;9)(p23;q34) translocation. Frequently associated with multilineage bone marrow dysplasia, it usually presents with anemia, thrombocytopenia (often pancytopenia), and other nonspecific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement (gingivitis, splenomegaly). Basophilia, as well as poor response to chemotherapy, has been reported.
No clinical trials have been registered for acute myeloid leukemia with t(6;9)(p23;q34).
2 publications have been identified in PubMed for acute myeloid leukemia with t(6;9)(p23;q34). Research spans Clinical Trial Publication (50%) and Basic Science / Preclinical (50%).
Andreozzi F (2026). [PMID: 42020760](https://pubmed.ncbi.nlm.nih.gov/42020760/). *Bone Marrow Transplant*. [Clinical Trial Publication]
Bruserud Ø (2025). [PMID: 41002427](https://pubmed.ncbi.nlm.nih.gov/41002427/). *Cells*. [Basic Science / Preclinical]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:17 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute myeloid leukemia with t(6;9)(p23;q34)